Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,083 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,116
- Phase 1823
- Phase 1/Phase 2481
- Phase 3349
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,083 total
- NCT05935358RecruitingPhase 4
Nuwiq added around surgery for people with hemophilia A
This Phase 4 study looks at how well Nuwiq works to manage bleeding risk around the time of major elective surgery in people with severe hemophilia A who already take emicizumab to prevent bleeds. It may help your surgical team plan safer blood-clotting support during and after surgery.
Dallas, TexasAges 12 years+ - NCT05936086Recruiting
Testing high-dose cyclophosphamide to treat adult HLH
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
ChongqingAges 18–65 - NCT05936580RecruitingPhase 4
Nuwiq dosing for girls and women with hemophilia A surgery
This trial studies how to dose Nuwiq (a factor medicine) and track outcomes in girls and women with hemophilia A who need major surgery. It may help confirm the best way to manage bleeding risk around surgery.
San Antonio, TexasAges 12 years+ - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT05937880Recruiting
Leflunomide for kids with stubborn Henoch-Schonlein purpura rash
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
Guangzhou, GuangdongAges 1–18 - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05942885Recruiting
Hypnosis for calming anxiety in lymphoma patients
This trial studies whether hypnosis can help reduce anxiety. It is meant for adults with certain types of lymphoma who are newly told their diagnosis and have anxiety symptoms.
Lyon, Pierre-BéniteAges 18 years+ - NCT05943067RecruitingPhase 1/Phase 2
Test of donor immune cells after stem cell transplant to prevent relapse
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
TübingenAges 2 months–65 years - NCT05943496RecruitingPhase 1
Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Portland, OregonAges 18 years+ - NCT05943457Recruiting
Vitamin K2 for adults with episodic migraine
This trial tests whether taking vitamin K2 can reduce the number of migraine days per month. It may help people who have had episodic migraines for at least a year and meet specific migraine frequency and medication requirements.
Beirut, BeirutAges 18 years+ - NCT05943522Recruiting
Study of asciminib in adults with Ph+ CML on Scemblix
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
Wŏnju, Gangwon-doAges 18–100 - NCT05945524Recruiting
Study of how teclistamab works in multiple myeloma patients
This study looks closely at patients’ immune cells to understand why teclistamab helps in multiple myeloma. Your participation could help doctors better predict who benefits and how the treatment works.
Amiens, FranceAges 18 years+ - NCT05946850Recruiting
Caudal pain block study for adults with chronic pain
This trial looks at giving a specific pain procedure called caudal analgesia to adults with long-term (chronic) pain. It may help reduce pain after the procedure, and it will compare results for people who can safely receive it.
Surrey, British ColumbiaAges 20–99 - NCT05947136Recruiting
PASCA program study after stem cell transplant for myeloma
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
ÉpagnyAges 18–70 - NCT05947344RecruitingPhase 1
Testing STI-8591 for advanced acute myeloid leukemia
This early-stage study tests STI-8591 in people with advanced acute myeloid leukemia (AML) or certain related blood cancers. It mainly aims to find a safe dose and see whether the treatment can work for patients whose disease did not respond to standard care or who cannot get it.
Hangzhou, ZhejiangAges 18 years+ - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05949944RecruitingPhase 1/Phase 2
Testing linperlisib plus CHOP for untreated peripheral T-cell lymphoma
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
Guangzhou, GuangdongAges 18 years+ - NCT05949125RecruitingPhase 1
CD123-positive AML trial testing an immune cell treatment
This Phase 1 trial tests an allogeneic immune-cell therapy for adults with CD123-positive acute myeloid leukemia (AML) that has not responded well to standard treatments. It aims to see whether this treatment can control leukemia after medicines and possibly transplant options are no longer suitable.
Ulm, Baden-WurttembergAges 18 years+ - NCT05950802RecruitingPhase 1
Improving how CAR T cells are timed for lymphoma outcomes
This Phase 1 trial tests a method to better time “cell therapy” (CAR T) called Yescarta in people with relapsed or refractory large B-cell lymphoma. The goal is to improve outcomes by optimizing how the body is prepared before CAR T treatment.
Toronto, OntarioAges 18 years+ - NCT05950750Recruiting
Living with aTTP? Join a national patient registry study
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
AnkaraAges 18 years+ - NCT05950997Recruiting
Test drug combo for newly diagnosed CLL in Chinese adults
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
Nanjin, JiangsuAges 18 years+ - NCT05951517Recruiting
Mycophenolate for stubborn stomach Purpura (HSP) in children
This trial looks at whether mycophenolate mofetil can help children ages 3–18 who have Henoch-Schönlein purpura affecting the gut that does not improve with steroid treatment. It may help reduce serious stomach symptoms like severe belly pain, bleeding, or bowel problems.
Guangzhou, GuangdongAges 3–18 - NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05953961Recruiting
90Y radiation compared with microwave ablation for small liver cancer
This trial compares two procedures to treat a small, single liver tumor that cannot be surgically removed. It aims to see which treatment works better for people with low blood protein (albumin), which can affect healing and outcomes.
New Orleans, LouisianaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,083 recruiting hematology studies from the U.S. registry right now, out of 7,730 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.